Hot flashes, heat intolerance, and episodes of flushing and sweating during benzodiazepine withdrawal are frequently misattributed to menopause, thyroid dysfunction, or anxiety. The symptom overlap is real and the misattribution is common. For perimenopausal or postmenopausal women tapering a benzodiazepine, the default clinical interpretation is hormonal; for men and younger women, the default is anxiety or autonomic hyperactivity without a specific cause. In both cases, the underlying mechanism — GABA-mediated disruption of central thermoregulation and autonomic balance — is often missed.
How Benzodiazepines Alter Thermoregulation
Body temperature is regulated centrally by the preoptic area of the hypothalamus, which integrates inputs from skin and core thermoreceptors and drives responses through autonomic outflow: vasoconstriction, vasodilation, sweating, and shivering. GABAergic neurons are a significant component of the preoptic circuitry, and chronic benzodiazepine exposure alters their function in ways that do not immediately reverse on discontinuation.
Benzodiazepines also affect autonomic balance more broadly. Long-term use produces reductions in sympathetic baseline activity that the nervous system partially accommodates through compensatory changes. When the drug is removed, the sympathetic nervous system rebounds, producing a state of sympathetic overactivity that is clinically recognizable: tachycardia, blood pressure lability, sweating, flushing, tremor, and heat intolerance. Thermoregulatory symptoms are one axis of this broader autonomic picture.
Secondary changes in serotonergic and noradrenergic signaling, both of which influence the hypothalamic thermal set point, contribute further. The result is a nervous system whose temperature regulation is genuinely dysregulated, not imagined.
What the Symptoms Look Like
Several features are characteristic of withdrawal-related temperature dysregulation.
Episodic hot flashes without hormonal trigger. Episodes occur without identifiable precipitants, often in cool rooms or during rest, and are not correlated with ambient temperature or activity. They can occur at any time of day or night.
Accompanying autonomic features. Flushing, sweating (often localized to the head and chest but sometimes whole-body), palpitations, tremor, and a sense of internal agitation typically accompany the thermal sensation. These features are frequently more prominent than the thermal feeling itself.
Temperature mismatch. Patients often feel intensely hot when external observers do not perceive them as warm to the touch, or feel cold when they are demonstrably warm. The internal sense of temperature is decoupled from the body’s actual state.
Night sweats. Drenching night sweats are common and frequently attributed to menopause in women and to sleep apnea or anxiety in men. When present in a patient tapering a benzodiazepine, withdrawal is a better-supported explanation than either alternative.
Cold intolerance alternating with heat intolerance. Some patients describe a pattern of feeling cold and shivering for hours, then hot and sweating, with rapid transitions. This is a thermoregulatory instability rather than a true temperature problem in either direction.
Time-locking to dose changes. Symptoms often worsen after reductions and improve with dose holds, which is diagnostic when observed.
Distinguishing From Menopause
For women in the perimenopausal or postmenopausal age range, several features help separate withdrawal-related thermal symptoms from hormonal ones.
Temporal relationship to the taper. Symptoms that intensified or began with benzodiazepine dose reductions, and that worsen after further reductions, are more likely to be withdrawal-related than hormonal. Symptoms that preceded any changes in the benzodiazepine prescription by years, and that follow an FSH and menstrual pattern consistent with menopausal transition, are more likely hormonal.
Associated autonomic features. Vasomotor menopausal symptoms occur with palpitations and sweating but generally without the broader autonomic picture (tremor, paresthesias, sensory hypersensitivity, GI symptoms) that accompanies benzodiazepine withdrawal.
Response to hormonal therapy. If hormone replacement is tried and produces incomplete or no improvement, the diagnostic weight shifts toward a non-hormonal etiology. Conversely, adequate response to hormonal therapy does not exclude a withdrawal contribution; both may be operative, and the question becomes how much each contributes.
Laboratory evaluation. FSH, LH, and estradiol clarify the hormonal status. Normal thyroid function should be confirmed but is not specific. Cortisol and metanephrines are reasonable to check if autonomic symptoms are prominent, largely to exclude other causes, though the results are typically unremarkable in withdrawal-related dysregulation.
Both conditions can coexist. A perimenopausal woman tapering a benzodiazepine may have both hormonal and withdrawal-related thermal symptoms, and distinguishing the contribution of each is often a matter of observing response to interventions rather than a clean diagnostic decision.
What Helps
Temperature dysregulation in withdrawal typically improves as the nervous system stabilizes, but the timeline can be long. Several strategies reduce symptom burden in the interim.
Pacing the taper. Since dose reductions often worsen thermal symptoms, slowing the pace or holding the dose during exacerbations is the most reliable intervention. The Maudsley Deprescribing Guidelines’ hyperbolic approach, with smaller reductions at lower doses, tends to produce less thermal disruption than linear protocols.
Environmental management. Cool environments, breathable fabrics, and layered clothing allow rapid adjustment to the unpredictable symptom pattern. Bedroom temperatures on the cool side with separate covers help with night sweats.
Autonomic stabilization techniques. Paced breathing, vagal maneuvers, and some patients’ use of cold stimuli (cold drinks, cool showers) provide short-term relief during episodes. The evidence base is mostly observational, but the interventions carry minimal risk.
Limited pharmacologic options. Medications specifically for thermal symptoms should be used cautiously. Beta-blockers can help with the cardiovascular component of autonomic symptoms but do not directly target thermoregulation. Clonidine, an alpha-2 agonist, is sometimes used off-label for withdrawal-related autonomic symptoms including vasomotor flushing; it has its own withdrawal issues and is best used time-limited. Gabapentin is sometimes used for vasomotor symptoms but introduces another medication with its own dependence profile. SSRIs, particularly for vasomotor symptoms in menopause, are an option but complicate the taper picture. Hormone replacement is appropriate for hormonally-driven symptoms but does not address the withdrawal contribution.
Time. For most patients, thermoregulatory symptoms improve substantially over the months following completion of the taper. Patients experiencing these symptoms during an active taper can reasonably expect improvement, although the timeline is individual.
What to Ask the Prescriber
For a patient whose thermal symptoms are being managed as if they were hormonal or anxiety-related, several specific questions reframe the conversation.
Whether the symptom pattern aligns with dose changes in the benzodiazepine. If the patient can reconstruct the temporal relationship, it is usually evident.
Whether the broader autonomic picture (tremor, paresthesias, sensory hypersensitivity, GI symptoms) is present. If multiple autonomic features are present, a unified explanation — withdrawal-related autonomic dysregulation — is more parsimonious than several unrelated diagnoses.
Whether the clinical management is working. Ongoing thermal symptoms on adequate hormone replacement, or on standard anxiety treatment, should prompt a reconsideration of the etiology rather than escalation of the current intervention.
Temperature dysregulation in benzodiazepine withdrawal is not an incidental complaint. It reflects a real autonomic dysregulation that the standard diagnostic defaults tend to miss. Recognizing it is the first step toward managing it as what it is.